Zacks upgrades Collegium Pharmaceutical stock to strong buy
Published on 10/20/2026 at 22:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSZacks rating change
- Zacks Research upgraded Collegium Pharmaceutical from strong sell to strong buy on October 17, 2026.
- Second-quarter 2026 revenue reached USD 199.88 million, up 6.00 percent year over year.
- Collegium Pharmaceutical stock costs EUR 20.70 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST.
- The next earnings release is scheduled for November 5, 2026.
Collegium Pharmaceutical (ISIN US19459J1043) stood at EUR 20.70 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST. MarketBeat reported on October 17, 2026 that Zacks Research upgraded the stock from strong sell to strong buy. The rating change adds a fresh analyst signal to a company whose latest quarter combined ADHD growth with pressure in its pain portfolio.
Revenue grows across the portfolio
In the second quarter of 2026, Collegium Pharmaceutical generated USD 199.88 million in revenue, a 6.00 percent increase from the prior-year quarter. The company recorded a GAAP net loss of USD 15.05 million, compared with net income of USD 12.00 million in the second quarter of 2025.
According to Benzinga, Jornay PM revenue rose 41.00 percent year over year to USD 46.10 million in the second quarter. Nucynta franchise revenue fell 24.00 percent to USD 35.20 million, illustrating the split between the ADHD and pain businesses.
What does November 5 add?
Seeking Alpha lists November 5, 2026 as the next earnings date, with a normalized earnings-per-share estimate of USD 1.86 and a revenue estimate of USD 216.03 million. The next report will therefore provide a quantified test of whether the second-quarter growth profile carried into the third quarter.
The company expects 2026 total product revenue of USD 825.00 million to USD 855.00 million, while adjusted EBITDA guidance stands at USD 445.00 million to USD 470.00 million. Jornay PM revenue guidance remains USD 190.00 million to USD 200.00 million, and Azstarys guidance is USD 65.00 million to USD 75.00 million.
Comparison with peers
Collegium Pharmaceutical: P/E 18.73, market capitalization USD 756.3 million.
Pfizer (NYSE, USD): up 2.34 percent, P/E 39.81, market capitalization USD 171.7 billion.
Bristol-Myers Squibb (NYSE, USD): up 4.88 percent, P/E 13.59, market capitalization USD 126.0 billion.
Collegium stock after hours
On Nasdaq, Collegium Pharmaceutical was last quoted at USD 23.23 on October 20, 2026 at 4:00 p.m. ET, before after-hours trading. The US-listed stock remains well below its 52-week high of USD 50.79, while its 52-week low stands at USD 21.43, both dated October 20, 2026.
Collegium Pharmaceutical was trading at EUR 20.70 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Collegium Pharmaceutical stock.
Collegium Pharmaceutical market facts
- Company: Collegium Pharmaceutical, Inc.
- ISIN: US19459J1043
- Ticker: COLL
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 10:00 p.m. CEST): EUR 20.70
- Market capitalization: USD 756.3 million (as of October 20, 2026)
- 52-week range: USD 21.43-50.79 (as of October 20, 2026)
- Sector / Industry: Healthcare / Specialty and generic pharmaceuticals
- Next earnings date: November 5, 2026
Market context: Market report S&P 500.
